Morning after pill advocates fight back
WASHINGTON, DC—The recent decision by Human Services Secretary Kathleen Sebelius to restrict the sale of the morning after pill Plan B One-Step, manufactured by Teva Health, has sparked heated controversy. On January 6, advocates for unrestricted access to the emergency contraceptive took their case to the President’s Council of Advisers on Science and Technology, asking them to determine the basis for the administration’s controversial decision last month to continue requiring that girls under age 17 must obtain a prescription to receive the morning after pill.
In brief presentations squeezed into a meeting of the President’s Council of Advisers on Science and Technology, five experts contested Secretary Sebelius’s rejection of the Food and Drug Administration’s (FDA) approval of over-the-counter-sale of the product. They were each allotted two minutes.
“We are asking you to work with us . . . to readdress this decision, find out how it was made and why,” Wayne C. Shields told John P. Holdren, the chairman of the council. Mr. Shields is president of the Association of Reproductive Health Professionals, a trade organization with offices in Washington. Francesca T. Grifo of the Union of Concerned Scientists quoted Secretary Sebelius’s December 7 letter, which rejected the Food and Drug Administration’s (FDA) plan to make Plan B One-Step available to girls younger than 17 without a prescription. She noted, “Secretary Sebelius used phrases like ‘based on my review’ and ‘my conclusion. This is exactly the situation which scientific integrity policies are created to prevent: namely, a non-scientist, political appointee overturning a decades-long process of scientific research and review both inside and outside of the FDA.”
Afterward, however, she and the other advocates said the issue did not involve “scientific integrity” as commonly understood. Mr. Shields said, “This not about fraud, not about misconduct, it is about standing up to the stated principles.”
As Obama’s adviser for science and technology, Mr. Holdren has no direct influence over either Secretary Sebelius or FDA Commissioner Margaret Hamburg. Thus, itis unclear how Sebelius’s decision regarding access to the morning after pill short of President Obama ordering her to reverse it. Shortly after Secretary Sebelius released her controversial decision, the president announced that he supported it. Mr. Holdren told the speakers: “I will communicate the concerns that were expressed here to my boss.” He also addressed the issue of scientific integrity: “What scientific integrity requires is that the clearest and most objective evidence be made available” to decision-makers. That does not necessarily guarantee that the scientific findings alone will determine the outcome.”